Persistent Asset Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Persistent Asset Partners’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Buy	+145,585	New	+$1.42M	0.58%	41

Other funds holding FDMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PWM

Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Persistent Asset Partners's FDMT Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 145,585 shares worth $1.94M. The stake represents 0.58% of the portfolio and ranks #41 among its holdings.

50 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Persistent Asset Partners held 145,585 shares of 4D Molecular Therapeutics worth $1.94M as of Q2 2026.
4D Molecular Therapeutics was a new Persistent Asset Partners position in Q2 2026.
4D Molecular Therapeutics made up 0.58% of Persistent Asset Partners's portfolio in Q2 2026, its #41 holding.
50 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.